«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年05期

页码:

436-439

栏目:

基础医学

出版日期:

2019-09-20

文章信息/Info

Title:

IL-6 induces ovarian cancer cell resistance to tamoxifen

文章编号:

1006-8147(2019)05-0436-04

作者:

马晓霞¹; 2; 孙 旸³; 马 瑞²; 崔志坤²; 王 越²; 郭小芹²; 邓为民¹

（1.天津医科大学免疫学系，天津300070；2.武警后勤学院病原生物学教研室，天津300309；3.武警特色医学中心妇产科，天津 300163）

Author(s):

MA Xiao-xia¹; 2;  SUN Yang³;  MA Rui²;  CUI Zhi-kun²;  WANG Yue²;  GUO Xiao-qin²;  DENG Wei-min¹

（1.Department of Immunology, Tianjin Medical University, Tianjin 300070, China; 2. Logistics University of People’s Armed Police Force, Tianjin 300309, China; 3.Department of Gynecology and Obstetrics, Armed Police Characteristic Medical Center, Tianjin 300163, China)

关键词:

IL-6; 卵巢癌细胞; 基因稳定转染与克隆筛选; 抗雌激素治疗耐药

Keywords:

interleukin-6;  ovarian cancer cells;  gene stable transfection and clonal screening;  anti-estrogen treatment resistance

分类号:

R737.31

DOI:

-

文献标志码:

A

摘要:

目的：研究IL-6在诱导卵巢癌细胞对他莫西芬（TAM）产生耐药中的作用。方法：选择A2780（不分泌IL-6，但表达其受体，且对TAM敏感）和CAOV3（高表达IL-6及其受体，且对TAM耐药）细胞作为研究模型，应用重组IL-6短期处理或将ss/as IL-6基因稳定转染至A2780（该数据已有文章发表）及CAOV3细胞，通过MTT、RT-PCR、ELISA等观察内源性及外源性IL-6是否影响卵巢癌细胞对TAM的敏感性。结果：经稳定转染得到IL-6中、高抑制表达的2个CAOV3/asIL-6细胞克隆，与空载体转染细胞CAOV3/pcDNA3.1+相比，IL-6分泌水平分别下降了63.82%和75.69%（P<0.05），其IL-6 mRNA水平与其分泌水平相似；外源性IL-6处理及内源性过表达IL-6均可诱导A2780 细胞对TAM产生耐药，而内源性抑制IL-6表达则可恢复CAOV3细胞对TAM的敏感性。结论：IL-6可诱导卵巢癌细胞对TAM产生耐药，IL-6有可能是卵巢癌抗雌激素治疗耐药中的重要一环，有望成为逆转卵巢癌抗雌激素治疗耐药的重要靶点。

Abstract:

Objective: To explore the effect of tamoxifen resistance caused by exogenous and endogenous IL-6 in ovarian cancer cells. Methods: A2780 and CAOV3 cells were used as research models； we retreated with exogenous IL-6 to obtain A2780/preIL-6 cells. The antisense IL-6 gene was stably transfected into CAOV3 cells, and the IL-6 mRNA and IL-6 secretion levels of stably transfected cells were detected by RT-PCR and ELISA. Ovarian cancer cell activity was measured by MTT assay. Results: CAOV3/asIL-6 with different IL-6 secretion levels were stably transfected, and their IL-6 secretion levels were decreased by 63.82% and 75.69%, respectively, compared with their untransfected cells CAOV3(P<0.05), and its IL-6 mRNA level was consistent with its secretion level;Exogenous IL-6, endogenous overexpression of IL-6 induced resistance to tamoxifen in A2780 cells, whereas inhibition of IL-6 expression restored the sensitivity of CAOV3 cells to tamoxifen. Conclusion: IL-6 can induce tamoxifen resistance in ovarian cancer cells. IL-6 may be an important part of anti-estrogen resistance in ovarian cancer, and it is expected to be an important factor in reversing the anti-estrogen resistance of ovarian cancer.

参考文献/References:

[1] de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen[J]. Int J Breast Cancer, 2011, 2011:232435
[2] Kim J, Lee J, Jang S Y, et al. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines[J].Oncol Rep, 2016, 35(5): 2553
[3] 牛秀珑,叶路,毛立群,等.雌激素受体亚型对乳腺癌MCF-7细胞生长及微环境中Th平衡的影响[J].中国肿瘤生物治疗杂志 ,2011, 18(5): 490
[4] Sisay M, Edessa D. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers[J]. Gynecol Oncol Res Pract, 2017, 4:18
[5] Penson R T, Kronish K, Duan Z, et al. Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel[J].Int J Gynecol Cancer, 2000,10(1): 33
[6] Nilsson M B, Langley R R, Fidler I J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine[J]. Cancer Res, 2005, 65(23): 10794
[7] 王越,郭小芹,牛秀珑,等.卵巢癌细胞IL-6、IL-8分泌与他莫西芬敏感性及MAPK、Akt活性和ER特异性位点磷酸化水平的关系[J].细胞与分子免疫学杂志, 2010, 26(1): 21
[8] 李芳菲,郭飞,田文艳,等.难治性卵巢癌的内分泌治疗[J].中国妇产科临床杂志, 2018,19(1): 89
[9] Trabert B, Brinton L A, Anderson G L, et al. Circulating estrogens and postmenopausal ovarian cancer risk in the women’s health initiative observational study[J].Cancer Epidemiol Biomark Prevent, 2016, 25(4): 648
[10] 王建六,宋文月,刘俊英,等.上皮性卵巢癌内分泌治疗体外实验研究[J].肿瘤, 2001(3): 166
[11] Kulbe H, Thompson R, Wilson J L, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells[J].Cancer Res,2007,67(2): 585
[12] Shen W H, Zhou J H, Broussard S R, et al. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor[J].Cancer Res, 2002, 62(16): 4746
[13] Auersperg N, Ziltener H. Re: reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells[J]. J Natl Cancer Inst, 2002, 94(16): 1255
[14] Syed V, Ulinski G, Mok S C, et al. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells[J]. J Natl Cancer Inst, 2002, 94(8): 617

相似文献/References:

[1]庞淑婉,李 宏,穆 轶,等.清热消炎颗粒解热作用及对血清中TNF-α、IL-1β、IL-6和PGE2影响的初步研究[J].天津医科大学学报,2015,21(06):488.
　PANG Shu-wan,LI Hong,MU Yi,et al.Preliminary study on the antipyretic effect of Qingrexiaoyan particles and?its influence on TNF-α, IL- 1β IL-6, PGE2 in serum[J].Journal of Tianjin Medical University,2015,21(05):488.
[2]杨宏伟,牛文彦.探讨uKIM-1、IL-6、T细胞亚群在脓毒症急性肾损伤中早期检测的意义[J].天津医科大学学报,2018,24(02):145.
　YANG Hong-wei,NIU Wen-yan.Value of measuring uKIM，IL-6 and T-cell subsets in sepsis patients with acute kidney injury[J].Journal of Tianjin Medical University,2018,24(05):145.
[3]杨筱青,赵莉莉,陈慧萍.妊娠期糖尿病患者血浆中TNF-α和IL-6的表达及意义[J].天津医科大学学报,2019,25(04):405.
　YANG Xiao-qing,ZHAO Li-li,CHEN Hui-ping.Expression and significance of TNF-α and IL-6 in plasma in patients with gestational diabetes[J].Journal of Tianjin Medical University,2019,25(05):405.
[4]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂 耐药[J].天津医科大学学报,2022,28(03):266.
　SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(05):266.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金资助项目（81502256,81572852）;天津市自然科学基金重点项目 (18JCZDJC33200，18YFZCSY00040)
作者简介 马晓霞（1993-），女，硕士在读，研究方向：肿瘤免疫；通信作者：邓为民，E-mail：dengweimin@tmu.edu.cn；郭小芹，E-mail： guoxiaoqinlet@163.com。

常用功能

更新日期/Last Update: 2019-10-11